Sativa Wellness Group #SWEL, the UK-based CBD business give London South East an operational update Watch Now
Here you go Shaun, search for MyGo. Loads of great reviews
Agreed good times are on their way. CDX, CAR-T phase 1 plans, COVID, Lupus trails, new autoimmune conditions, mice drug machines, CDX toxicity reducing equalities.
CDX conditioning antibody can increase treatment dose (5 to 15 times) / decrease toxicity
. 20 suitable drugs being trailed in USA that have been identified by Hemo, some have been tested on (5>15 times) https://youtu.be/WK9FrOukj-w
. 101 failed autoimmune trails 2018, CDX can help
. Est $100b to $300b stranded asset in 2018 alone!!!
I'd watch out for companies using "pseudo gold standard' tests as baselines for their testing. I hear some companies results have been misrepresented by 28%. Ask the Guardian newspaper or Lennard Lee who is running CONDOR LFT tests and shared article which flags ODX for skewing results by 28%.
Going into an exam i would not want the examiner gunning before me because i cheated on my course work.
Top notch estimating Shaun, much appreciated :-) Mouth watering and I think you have been a little conservitive.
With regards to PCR detection of viral load, if it is increased those who are presymptomatic or asymptomatic with same load levels as those with dead virus will be missed. In key settings its no good detecting only the most infectious.
The LightCycler 2 has been discontinued since 2018. Wonder if Roche failed at building their own.
Hearting the spreadsheet
Should have added although unit sales pale in comparison to test sales a purchase would secure exclusive supply for Nova which is far more valuable than units sales of 300x£10k, 700 units in phase 2.....
There are some valuations for competitors of IT-IS at end of doc https://tracxn.com/d/companies/mygopcr.com
There's barely any money in machine sales. Nova are relabeling units with some customisation to software. IT-IS have been supplying Q32's to Nova since 2014. They signed a world wide exclusive deal with Roche in 2011.
Possible "vertical integration" target?
#Novacyt significant US sales ??
Q16 on sale in 40 States
"US is one of Novacyt's top preforming countries for sales but given the scale of opportunity there is scope significant growth"
"Looking to expand in States through organic investment & M&A"
Test consumables £24 a test
US gov will reimburse $120 per test
Wilson63 there's nothing Tay has that could be market sensitive as he's just a PI. Some info maybe conjecture and awaiting more evidence. Definitely no market sensitive info.
For a peak at what he might be alluding to check out some of his recent tweets https://twitter.com/TaylorQuant?s=09
"The US is one of Novacyt's top preforming countries for sales but given the scale of opportunity there is scope significant growth for more"
"Looking to expand in States through organic investment and M&A"
Thank you for your patience today, I appreciate trying to gain access to watch the AGM may have been frustrating due to the external outage, but I hope most of you managed it in the end!
The results and presentation are now up on the website with a video of the actual meeting to follow once it has been compressed and transferred for me to upload in the morning. www.novacyt.com
Once again, thank you so much for your help in making us quorate for the meeting today and the continued support and trust shown in Novacyt by all Shareholders.
Much props for Tay for summarising AGM. He'll get a tweet out tomorrow.
Excellent meeting, some massive figures within the detail.
Q. Are manufacturing sub contractors eroding profit?
A. No - they went from reserach use products to clinical
. Margin have been maintained as Clinicial products offer higher profit margins, offsetting the need to outsource manufacturing
. UK Corporration tax is 19% but they're reducing it through the UK's 'Patent Box' scheme. Takes their tax down to 10 to 12%
. Recruited 60+ staff members
. 20 mill cash in bank June AFTER increasing inventory by 13 million and clearing over 8 million in debts
. wanted to take opportunity as early as possible to become debt free
. Now - investing in inventory. Their selling point now is that they can make significant amounts of stock but ALSO deliver fast when needed
. NCYT does not have high capital expenditure, expanded by being efficient and using outsourcing
. manufacturing increased 100 times in 4 months since Feb
. US is largest COVID market and one of Novacyt’s top preforming countries. Nova are developing relationships to increase market share (see question 6)
. Commitment to CONTINUE to innovate as pandemic continues
. Saliva trial currently in London and care Homes
. Major care homes trails are coming to an end
. Transformational contract! (see RNS)
. Phase 1 - £250 million contract can go up. or down.. depends how well NHS use reagents
. Phase 2 - contarct determined by. success of Phase 1.
. I estimate Phase 1 & 2 contracts could be worth £500m > £750m over 12 months
. UK is currently their only direct prescence in a key market.. but they will change that now
. they will add revenues and growth to offset loss of covid 19 in the fture
. COVID-19 revenue will NOT drop off in the near future. In fact they believe COVID testing will increase
. They have competitive advantage as they work close with government and DSC
. Expect to SIGNIFICANTLY exceed 2020 1st half sales
. Continued and very strong sales into 2021 and they cant see a drop off point at this stage
. Market will be updated
. They see no material change in margins any time soon (83% to 85%)
. They going to move rapidly, Q1 and Q2 2021, Big acquisitions
1 - Current and future plans and supply constraints?
1A - they built a. flexible supply chain and manufacturing
2 - Plans for products in covid 19 after antobody test release?
2A. - Commited to innovate in covid 19 testing AND in respiratory markets, they WILL address unmet needs. Will update at later date
3 - France progress with 2 gene?
3A - Test now available and reimburseable
4 - Beyond COVID-19 what are next areas?
4A - Market areas in respiratory and clincal diaagnostic markets
5 - How do you see competeition, NCYTs USP, risks, oipportunities as CEO?
5A - total market 70 billion and EXCLUDES. covid 19 testing, some analysts repor
Thank you for registering to view the Novacyt AGM due to be held on 29th September.
In an effort to ensure only shareholders join the meeting, could you please confirm by return which exchange you currently hold your shares on and if they are held with in a nominee account or similar, if so which one?
If you have recently confirmed these details by submitting a vote to the AGM, then please ignore this request. Alternatively, if you have not voted for the AGM then can we please encourage you to do so this evening as we need as many votes as possible to be quorate this year. I have attached a voting form which I will need to be signed and returned along with a proof of holding screen shot – the deadline for votes is this evening so this is one last attempt to drum up any final votes!
Had email from Mandy, still taking votes. Slow worms it's not too late.
Get us over the 25% requires to invoke Extraordinary Measures
Print out or mark up this proxy form https://novacyt.com/wp-content/uploads/2020/09/NOVACYT-Formulaire-de-vote-AG.pdf
sign and then email it along with proof of your share holding ( screen shot) to firstname.lastname@example.org
If you wish to see the resolutions here they all are: https://novacyt.com/wp-content/uploads/2020/09/NVT-SOC-Text-of-resolutions.pdf
Boxes to fill, if in agreement https://mobile.twitter.com/Larry64450205/status/1309058547586662404